[ESPR] Esperion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 13.18 Change: 0.52 (4.11%)
Ext. hours: Change: 0 (0%)

chart ESPR

Refresh chart

Strongest Trends Summary For ESPR

ESPR is in the medium-term down -33% below S&P in 1 year. In the long-term down -37% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase IIb clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic apoA-I therapy that is in pre-clinical trials for treating patients with acute coronary syndrome. The company is headquartered in Plymouth, Michigan.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-12.29% ROE-12.71% ROI
Current Ratio40.33 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities190.41 M Cash From Investing Activities-57.55 M Cash From Operating Activities-9.26 M Gross Profit
Net Profit-11.47 M Operating Profit-11.43 M Total Assets325.22 M Total Current Assets279.83 M
Total Current Liabilities6.94 M Total Debt4.88 M Total Liabilities10.79 M Total Revenue
Technical Data
High 52 week59.11 Low 52 week36.99 Last close37.71 Last change-3.36%
RSI22.75 Average true range1.65 Beta1.81 Volume98.17 K
Simple moving average 20 days-8.5% Simple moving average 50 days-17.36% Simple moving average 200 days-18.33%
Performance Data
Performance Week-2.48% Performance Month-19.34% Performance Quart-24.84% Performance Half-16.7%
Performance Year-18.66% Performance Year-to-date-18.02% Volatility daily1.86% Volatility weekly4.15%
Volatility monthly8.51% Volatility yearly29.48% Relative Volume258.64% Average Volume447.01 K
New High New Low

News

2020-06-05 11:31:03 | Why Is Esperion Therapeutics ESPR Down 1.5% Since Last Earnings Report?

2020-06-04 12:00:04 | All You Need to Know About Esperion Therapeutics ESPR Rating Upgrade to Buy

2020-06-04 07:00:10 | Esperion Announces Commercial Availability of NEXLIZET™ bempedoic acid and ezetimibe Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

2020-05-27 08:00:10 | Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020

2020-05-15 18:00:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-05-08 14:49:46 | Analysts Are Upgrading Esperion Therapeutics, Inc. NASDAQ:ESPR After Its Latest Results

2020-05-07 11:47:03 | Esperion ESPR Q1 Earnings and Revenues Beat Estimates

2020-05-07 09:01:12 | Esperion Therapeutics Inc ESPR Q1 2020 Earnings Call Transcript

2020-05-07 08:00:10 | Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference

2020-05-07 07:29:47 | Edited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-06 18:55:10 | Esperion Therapeutics ESPR Reports Q1 Loss, Tops Revenue Estimates

2020-05-06 16:05:10 | Esperion Reports First Quarter 2020 Financial Results and Provides Company Update

2020-04-30 08:00:10 | Esperion to Report First Quarter 2020 Financial Results May 6, 2020

2020-04-21 07:01:33 | Industry Analysts Just Upgraded Their Esperion Therapeutics, Inc. NASDAQ:ESPR Revenue Forecasts By 15%

2020-04-20 07:00:10 | Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ bempedoic acid and NEXLIZET™ bempedoic acid and ezetimibe Tablets in Japan

2020-04-18 10:59:36 | Were Hedge Funds Right About Selling Esperion Therapeutics ESPR?

2020-04-09 08:00:10 | Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference

2020-04-07 10:43:02 | Esperion's Cholesterol Drugs Receive Approval in Europe

2020-04-06 07:05:10 | Esperion Announces European Commission Approval of the NUSTENDI™ bempedoic acid and ezetimibe Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

2020-04-06 07:00:10 | Esperion Announces European Commission Approval of the NILEMDO™ bempedoic acid Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

2020-04-05 08:26:18 | Revenue Downgrade: Here's What Analysts Forecast For Esperion Therapeutics, Inc. NASDAQ:ESPR

2020-03-30 16:15:10 | Esperion Announces Commercial Availability of the NEXLETOL™ bempedoic acid Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

2020-03-28 11:30:03 | Esperion Therapeutics ESPR Down 32.5% Since Last Earnings Report: Can It Rebound?

2020-03-28 09:30:10 | Esperion Announces Three Data Presentations of the NEXLETOL™ bempedoic acid Tablet and the NEXLIZET™ bempedoic acid and ezetimibe Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology ACC.

2020-03-23 07:30:10 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ bempedoic acid Tablet and Phase 2 Study Results of the NEXLIZET™ bempedoic acid and ezetimibe Tablet to be Presented at the American College of Cardiology’

2020-03-18 07:30:10 | Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors

2020-02-28 16:15:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-02-28 08:12:01 | Esperion ESPR Q4 Earnings and Revenues Beat Estimates

2020-02-28 07:00:10 | Esperion to Participate in Upcoming Investor Conferences

2020-02-27 10:15:03 | Esperion Therapeutics ESPR Reports Q4 Loss, Tops Revenue Estimates

2020-02-27 07:35:07 | The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

2020-02-27 07:00:10 | Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-26 17:30:10 | Esperion Announces FDA Approval of the NEXLIZET™ bempedoic acid and ezetimibe Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

2020-02-21 16:38:10 | Esperion Announces FDA Approval of NEXLETOL™ bempedoic acid Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

2020-02-21 16:27:15 | Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval

2020-02-16 15:03:32 | The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions

2020-02-03 13:30:16 | Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020-01-31 07:02:10 | Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

2020-01-31 07:01:10 | Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

2020-01-27 12:20:13 | One Thing To Remember About The Esperion Therapeutics, Inc. NASDAQ:ESPR Share Price

2020-01-07 07:30:10 | Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference

2020-01-03 16:15:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-12-12 11:59:58 | Did Hedge Funds Drop The Ball On Esperion Therapeutics ESPR ?

2019-12-06 11:31:04 | Esperion Therapeutics ESPR Up 25.1% Since Last Earnings Report: Can It Continue?

2019-11-28 07:09:12 | Esperion's Promising Drugs Under Review, Funds a Concern

2019-11-22 18:30:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-11-19 09:13:02 | Esperion Therapeutics ESPR Catches Eye: Stock Jumps 10%

2019-11-17 15:05:00 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

2019-11-12 11:05:00 | Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

2019-11-10 07:56:48 | President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. NASDAQ:ESPR